Krystal Biotech operates in a specialized sector of genomic medicine and rare disease therapeutics, facing varying degrees of competition depending on the specific therapeutic area it targets. While its flagship product currently occupies a unique position as the first approved redosable topical gene therapy for dystrophic epidermolysis bullosa, the company faces broad competitive pressures from other biotechnology firms developing advanced gene delivery platforms, mRNA therapies, and CRISPR gene-editing tools. Competitors include large-scale biopharmaceutical enterprises investing heavily in rare dermatological conditions, as well as nimble, early-stage genomics startups attempting to engineer alternative vectors or localized delivery mechanisms for ophthalmic, pulmonary, and oncological indications. The competitive landscape is defined by rapid scientific innovation, where protecting intellectual property and achieving superior clinical efficacy are paramount.